Open Access

Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis

  • Authors:
    • Yoshiki Naito
    • Hiroto Ishikawa
    • Eiji Sadashima
    • Yoshinobu Okabe
    • Kenjiro Takahashi
    • Ryuichi Kawahara
    • Toru Hisaka
    • Masaru Fukahori
    • Tomoyuki Ushijima
    • Yusuke Ishida
    • Masahiko Tanigawa
    • Yutaro Mihara
    • Masamichi Nakayama
    • Reiichiro Kondo
    • Hironori Kusano
    • Yorihiko Takase
    • Hideyuki Abe
    • Etsuyo Ogo
    • Koji Okuda
    • Kazuhide Shimamatsu
    • Hirohisa Yano
    • Jun Akiba
  • View Affiliations

  • Published online on: June 20, 2019     https://doi.org/10.3892/mco.2019.1885
  • Pages: 225-233
  • Copyright: © Naito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Borderline resectable pancreatic head cancer (BR‑PHC) has low resectability due to vascular invasion. Although the clinical effects of neoadjuvant chemoradiotherapy (NAC‑RT) for BR‑PHC have been examined, few studies have reported its pathological aspects. The present study retrospectively investigated the effect of NAC‑RT on the histological features of BR‑PHC. A total of 29 patients with BR‑PHC who underwent NAC‑RT, and 55 controls with resectable PHC, who underwent pancreaticoduodenectomy at the Kurume University Hospital. Tumor staging, lymphovascular invasion (LVI), and microvessel invasion (MVI) were evaluated. The median tumor size in the NAC‑RT group was 2.0 cm, and it was smaller than that of the control group (P=0.006). The rates of lymph node metastasis, LVI, and MVI were significantly lower in the NAC‑RT group (P<0.001, 0.002, and 0.015, respectively). Overall survival in the NAC‑RT group was comparable to that in the control group, although patients with BR‑PHC generally had a poorer prognosis than those with resectable PHC. Patients in the NAC‑RT group without portal vein invasion (PVI) had a significantly better prognosis than those with PVI in the control group (P=0.002). NAC‑RT may be beneficial for patients with BR‑PHC by inhibiting local invasion and metastasis as prognosis following resection could be equivalent to that of patients with conventional ductal adenocarcinoma.

References

1 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI

2 

Egawa S, Toma H, Ohigashi H, Okusaka T, Nakao A, Hatori T, Maguchi H, Yanagisawa A and Tanaka M: Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas. 41:985–992. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, et al: Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 28:219–230. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, et al: 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 10:1199–1210; discussion 1210–1191. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF and Jaques DP: Defining morbidity after pancreaticoduodenectomy: Use of a prospective complication grading system. J Am Coll Surg. 204:356–364. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Kimura H, Ohtsuka T, Matsunaga T, Watanabe Y, Tamura K, Ideno N, Aso T, Miyazaki T, Osoegawa T, Aishima S, et al: Predictors and diagnostic strategies for early-stage pancreatic ductal adenocarcinoma: A retrospective study. Pancreas. 44:1148–1154. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Serrano PE, Cleary SP, Dhani N, Kim PT, Greig PD, Leung K, Moulton CA, Gallinger S and Wei AC: Improved long-term outcomes after resection of pancreatic adenocarcinoma: A comparison between two time periods. Ann Surg Oncol. 22:1160–1167. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD and Berry DP: Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP. 9:99–132. 2008.PubMed/NCBI

9 

Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W and Palmer DH: Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol. 15:333–348. 2018. View Article : Google Scholar : PubMed/NCBI

10 

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH and Neoptolemos JP: Pancreatic cancer. Nat Rev Dis Primers. 2:160222016. View Article : Google Scholar : PubMed/NCBI

11 

Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Xu Y, Guo X, Fan Y, Wang D, Wu W, Wu L, Liu T, Xu B, Feng Y, Wang Y, et al: Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Jpn J Clin Oncol. 48:535–541. 2018. View Article : Google Scholar : PubMed/NCBI

13 

Sherman WH, Hecht E, Leung D and Chu K: Predictors of response and survival in locally advanced adenocarcinoma of the pancreas following neoadjuvant GTX with or without radiation therapy. Oncologist. 23:4–e10. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, et al: Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 268:215–222. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Kodera Y and Nakao A: Aggressive surgery for borderline resectable pancreatic cancer: Evaluation of national comprehensive cancer network guidelines. Pancreas. 42:1004–1010. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T, Hayasaki A, Katz MHG, Kim SW, Kishiwada M, et al: International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 18:2–11. 2018. View Article : Google Scholar : PubMed/NCBI

17 

Ishikawa O, Ohigashi H, Imaoka S, Furukawa H, Sasaki Y, Fujita M, Kuroda C and Iwanaga T: Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg. 215:231–236. 1992. View Article : Google Scholar : PubMed/NCBI

18 

Uchida K and Masugi Y: Histological assessment of therapeutic response. Classification of Pancreatic Carcinoma: Japan Pancreas Society. Isaji S: Kanehara & Co., Ltd.; Tokyo: pp. 117–122. 2017

19 

Ushijima T, Okabe Y, Ishida Y, Sugiyama G, Sasaki Y, Kuraoka K, Yasumoto M, Taira T, Naito Y, Nakayama M, et al: Evaluation of endoscopic cytological diagnosis of unresectable pancreatic cancer prior to and after the introduction of endoscopic ultrasound-guided fine-needle aspiration. Mol Clin Oncol. 2:599–603. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Nakama Y, Kawahara R, Nomura Y, Muroya D, Arai S, Ishikawa H, Yasunaga M, Horiuchi H, Akagi Y, Tanaka H, et al: A case of pancreatic head cancer showing pathological complete response to neoadjuvant chemoradiation therapy. Gan To Kagaku Ryoho. 42:2376–2378. 2015.(In Japanese). PubMed/NCBI

21 

Ravikumar R, Sabin C, Abu Hilal M, Bramhall S, White S, Wigmore S, Imber CJ and Fusai G; UK Vascular Resection in Pancreatic Cancer Study Group, : Portal vein resection in borderline resectable pancreatic cancer: A United Kingdom multicenter study. J Am Coll Surg. 218:401–411. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, Schurr PG, Liebl L, Thieltges S, Gawad KA, et al: En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: Perioperative outcome and long-term survival in 136 patients. Ann Surg. 247:300–309. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA and Evans DB: Pancreaticoduodenectomy with vascular resection: Margin status and survival duration. J Gastrointest Surg. 8:935–949; discussion 949–950. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 27:1806–1813. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Hamada Y and Nakayama Y: Aggressive venous invasion in the area of carcinoma correlates with liver metastasis as an index of metastasis for invasive ductal carcinoma of the pancreas. Pancreatology. 17:951–955. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Nagakawa Y, Aoki T, Kasuya K, Tsuchida A and Koyanagi Y: Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas. 24:169–178. 2002. View Article : Google Scholar : PubMed/NCBI

27 

Naito Y, Suda K, Nobukawa B, Kinoshita H and Kojiro M: Histopathological study of invasive ductal carcinoma (IDC) of the pancreas without associated cancerous occlusion of the main pancreatic duct. J Hepatobiliary Pancreat Surg. 13:556–561. 2006. View Article : Google Scholar : PubMed/NCBI

28 

Yamasaki S, Suda K, Nobukawa B and Sonoue H: Intraductal spread of pancreatic cancer. Clinicopathologic study of 54 pancreatectomized patients. Pancreatology. 2:407–412. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, Lee JE, Pisters PW, Vauthey JN, Crane C, et al: Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: A predictor for patient outcome. Cancer. 118:3182–3190. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, et al: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 23:1237–1244. 2005. View Article : Google Scholar : PubMed/NCBI

31 

Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, Ajani JA and Swisher SG: Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome. Am J Surg Pathol. 31:58–64. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D and Sheahan K: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 47:141–146. 2005. View Article : Google Scholar : PubMed/NCBI

33 

Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et al: Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101. JAMA Surg. 151:e1611372016. View Article : Google Scholar : PubMed/NCBI

34 

Okada KI, Hirono S, Kawai M, Miyazawa M, Shimizu A, Kitahata Y, Ueno M, Hayami S and Yamaue H: Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 37:853–858. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Okada KI, Shimokawa T, Hirono S, Kawai M, Sho M, Satoi S, Matsumoto I, Eguchi H, Murakami Y, Yamada S, et al: Effect of neoadjuvant nab-paclitaxel plus gemcitabine therapy on overall survival in patients with borderline resectable pancreatic cancer: A prospective multicenter phase II trial (NAC-GA Trial). Oncology. 93:343–346. 2017. View Article : Google Scholar : PubMed/NCBI

36 

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol. 29:4548–4554. 2011. View Article : Google Scholar

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Naito, Y., Ishikawa, H., Sadashima, E., Okabe, Y., Takahashi, K., Kawahara, R. ... Akiba, J. (2019). Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis. Molecular and Clinical Oncology, 11, 225-233. https://doi.org/10.3892/mco.2019.1885
MLA
Naito, Y., Ishikawa, H., Sadashima, E., Okabe, Y., Takahashi, K., Kawahara, R., Hisaka, T., Fukahori, M., Ushijima, T., Ishida, Y., Tanigawa, M., Mihara, Y., Nakayama, M., Kondo, R., Kusano, H., Takase, Y., Abe, H., Ogo, E., Okuda, K., Shimamatsu, K., Yano, H., Akiba, J."Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis". Molecular and Clinical Oncology 11.3 (2019): 225-233.
Chicago
Naito, Y., Ishikawa, H., Sadashima, E., Okabe, Y., Takahashi, K., Kawahara, R., Hisaka, T., Fukahori, M., Ushijima, T., Ishida, Y., Tanigawa, M., Mihara, Y., Nakayama, M., Kondo, R., Kusano, H., Takase, Y., Abe, H., Ogo, E., Okuda, K., Shimamatsu, K., Yano, H., Akiba, J."Significance of neoadjuvant chemoradiotherapy for borderline resectable pancreatic head cancer: Pathological local invasion and microvessel invasion analysis". Molecular and Clinical Oncology 11, no. 3 (2019): 225-233. https://doi.org/10.3892/mco.2019.1885